← Leaderboards
Lauren M Slosky
University Of Minnesota
$1,940,735
Attributed
$2,650,086
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $965.2K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,650,086 · 4
By mechanism
R01$1,418,702 · 1
R00$747,000 · 1
K99$360,831 · 1
F32$123,553 · 1
Top collaborators
- Steven H Olson2 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Dezhi Liao$5,861,824
- Patrick Rothwell$8,678,718
- Alonso Guedes$1,506,798
- Matthew Carl Hearing$4,781,466
- Jonathan Gewirtz$1,888,065
Others in their field
Other Emerging Leaders on “Pathway Interactions”
- April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
- Kevin Urdahl · Seattle Children'S Hospital$47,227,116
- Urs Ochsner · Crestone, Inc.$38,569,476
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Jeffrey Glenn · Stanford University$26,017,226
Research focus
Pathway InteractionsPublic HealthGtp-Binding ProteinsNormalcyPhysiologicalPsychostimulantComplexG-Protein-Coupled ReceptorsLigandsNeurotensin ReceptorsPharmaceutical PreparationsDopaminePropertyAttenuatedAgonistBehaviorAddictionDopamine D2 ReceptorBeta-ArrestinLead SeriesMesolimbic SystemMethamphetamineBrainSelf Administration
Grant awards (11)
Neurotensin receptor 1 as a novel target for opioid use disorder and discovery of new small molecule probes$702,476
R01 · FY2025 · DA · contact PI
Neurotensin receptor 1 as a novel target for opioid use disorder and discovery of new small molecule probes$716,226
R01 · FY2024 · DA · contact PI
Leveraging Functional Selectivity in the Neurotensin Receptor 1-Mediated Treatment of Addiction$249,000
R00 · FY2024 · DA · contact PI
Leveraging Functional Selectivity in the Neurotensin Receptor 1-Mediated Treatment of Addiction$249,000
R00 · FY2023 · DA · contact PI
Leveraging Functional Selectivity in the Neurotensin Receptor 1-Mediated Treatment of Addiction$249,000
R00 · FY2022 · DA · contact PI
Leveraging Functional Selectivity in the Neurotensin Receptor 1-Mediated Treatment of Addiction$121,905
K99 · FY2021 · DA · contact PI
Leveraging Functional Selectivity in the Neurotensin Receptor 1-Mediated Treatment of Addiction$119,463
K99 · FY2020 · DA · contact PI
Leveraging Functional Selectivity in the Neurotensin Receptor 1-Mediated Treatment of Addiction$119,463
K99 · FY2019 · DA · contact PI
Biased Agonism at Neurotensin Receptor 1 for the Treatment of Methamphetamine Addiction$7,821
F32 · FY2019 · DA · contact PI
Biased Agonism at Neurotensin Receptor 1 for the Treatment of Methamphetamine Addiction$59,038
F32 · FY2018 · DA · contact PI
Biased Agonism at Neurotensin Receptor 1 for the Treatment of Methamphetamine Addiction$56,694
F32 · FY2017 · DA · contact PI